Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

Name: Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
License: Public Domain

National Cancer Institute (NCI)

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

metastatic large cell neuroendocrine carcinoma, metastatic neuroendocrine carcinoma, metastatic neuroendocrine neoplasm, metastatic small cell neuroendocrine carcinoma

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 394775
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.